

Title (en)

COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES

Title (de)

ZUSAMMENGESETZTES PRÄPARAT MIT EINEM NEUARTIGEN 3-(4-(BENZYLOXY)PHENYL)HEX-4-INONENSÄURE-DERIVAT UND EINEM ANDEREN WIRKSTOFF ZUR VORBEUGUNG ODER BEHANDLUNG VON STOFFWECHSELERKRANKUNGEN

Title (fr)

PRÉPARATION COMPOSITE, CONTENANT UN NOUVEAU DÉRIVÉ DE L'ACIDE 3-(4-(BENZYLOXY)PHÉNYL)HEX-4-INOÏQUE ET UN AUTRE PRINCIPE ACTIF, ET DESTINÉE À PRÉVENIR OU TRAITER LES MALADIES MÉTABOLIQUES

Publication

EP 3207928 A4 20180314 (EN)

Application

EP 15850582 A 20151016

Priority

- KR 20140141216 A 20141017
- KR 2015010976 W 20151016

Abstract (en)

[origin: EP3207928A2] The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPP4) inhibitor-based, sulfonyleurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X.

IPC 8 full level

A61K 31/357 (2006.01); **A61K 31/192** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01)

CPC (source: CN EP RU US)

A61K 9/0019 (2013.01 - US); **A61K 9/14** (2013.01 - US); **A61K 9/20** (2013.01 - US); **A61K 9/48** (2013.01 - US); **A61K 31/192** (2013.01 - CN EP US); **A61K 31/357** (2013.01 - CN EP RU US); **A61K 31/40** (2013.01 - CN EP US); **A61K 31/4035** (2013.01 - CN EP RU US); **A61K 31/435** (2013.01 - RU); **A61K 31/44** (2013.01 - EP US); **A61K 31/4418** (2013.01 - CN); **A61K 31/445** (2013.01 - EP US); **A61K 31/454** (2013.01 - CN EP US); **A61K 31/47** (2013.01 - EP RU US); **A61K 31/472** (2013.01 - CN); **A61K 31/495** (2013.01 - CN EP US); **A61K 31/496** (2013.01 - CN EP RU US); **A61K 31/506** (2013.01 - CN EP US); **A61K 45/06** (2013.01 - US); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP RU); **A61P 5/50** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07C 59/72** (2013.01 - CN US); **C07C 59/90** (2013.01 - CN); **C07D 207/06** (2013.01 - CN EP US); **C07D 209/44** (2013.01 - CN EP RU US); **C07D 211/14** (2013.01 - CN EP US); **C07D 211/70** (2013.01 - CN EP US); **C07D 213/55** (2013.01 - RU); **C07D 213/84** (2013.01 - CN); **C07D 215/06** (2013.01 - EP US); **C07D 217/04** (2013.01 - CN RU); **C07D 239/42** (2013.01 - CN); **C07D 241/04** (2013.01 - RU); **C07D 271/07** (2013.01 - CN); **C07D 277/82** (2013.01 - CN); **C07D 295/096** (2013.01 - CN EP US); **C07D 317/72** (2013.01 - CN EP RU US); **C07D 401/04** (2013.01 - EP US); **C07D 403/04** (2013.01 - EP US); **C07D 413/04** (2013.01 - CN EP US); **C07D 417/04** (2013.01 - EP US)

Citation (search report)

- [Y] WO 2005086661 A2 20050922 - AMGEN INC [US], et al
- [Y] WO 2008001931 A2 20080103 - TAKEDA PHARMACEUTICAL [JP], et al
- [Y] WO 2011046851 A1 20110421 - LILLY CO ELI [US], et al
- See references of WO 2016060517A2

Cited by

US11964938B2; JP2023512757A; KR20200108318A; US2020399198A1; AU2019205093B2; WO2019134984A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

EP 3207928 A2 20170823; EP 3207928 A4 20180314; EP 3207928 B1 20210310; AU 2015331074 A1 20170518; AU 2015331074 B2 20181115; BR 112017007720 A2 20171219; BR 112017007720 B1 20230117; CA 2960944 A1 20160421; CA 2960944 C 20190910; CN 106715409 A 20170524; CN 106715409 B 20200911; CN 111423408 A 20200717; DK 3207928 T3 20210426; ES 2869910 T3 20211026; ES 2869910 T8 20220201; JP 2017534582 A 20171124; JP 6458136 B2 20190123; KR 101728900 B1 20170424; KR 20160046306 A 20160428; MX 2017004614 A 20170620; PL 3207928 T3 20210823; RU 2680248 C1 20190219; SA 517381320 B1 20210712; US 10821110 B2 20201103; US 2017296539 A1 20171019; WO 2016060517 A2 20160421; WO 2016060517 A3 20160915

DOCDB simple family (application)

EP 15850582 A 20151016; AU 2015331074 A 20151016; BR 112017007720 A 20151016; CA 2960944 A 20151016; CN 201580050675 A 20151016; CN 202010089772 A 20151016; DK 15850582 T 20151016; ES 15850582 T 20151016; JP 2017515685 A 20151016; KR 2015010976 W 20151016; KR 20150144852 A 20151016; MX 2017004614 A 20151016; PL 15850582 T 20151016; RU 2017113130 A 20151016; SA 517381320 A 20170416; US 201515511955 A 20151016